Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.45 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | CDK4 | P11802 | 2/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.45 |
| ▸ | CCND1 | P24385 | 2/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2087968 | 0.88 | PTGS1 (0.51) | EGLN1PTGS1PTGS2CCNB2CCNE2 | |
| Bromide SCHEMBL2087132 | 0.87 | PTGS1 (0.50) | EGLN1PTGS1PTGS2CCNB2CCNE2 | |
| SCHEMBL2087833 | 0.85 | PTGS1 (0.45) | EGLN1PTGS1PTGS2MAPTPOLB | |
| SCHEMBL327269 | 0.84 | PTGS1 (0.54) | EGLN1PTGS1PTGS2CCNB2CCNE2 | |
| SCHEMBL30845741 | 0.84 | EGLN1 (0.52) | EGLN1PTGS1PTGS2CCNB2CCNE2 | |
| SCHEMBL2087802 | 0.84 | PTGS1 (0.46) | EGLN1PTGS1PTGS2CDK4CDK2 | |
| SCHEMBL2086678 | 0.83 | PTGS1 (0.43) | EGLN1PTGS1PTGS2MAPTPOLB | |
| SCHEMBL2085892 | 0.82 | RAB9A (0.50) | EGLN1PTGS1PTGS2CDK5MAPT | |
| SCHEMBL2086685 | 0.82 | EGLN1 (0.44) | EGLN1PTGS1PTGS2CYP3A4MAPT | |
| SCHEMBL2088899 | 0.82 | RAB9A (0.43) | EGLN1PTGS1PTGS2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902219-B2 | 2-benzoylimidazopyridine derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-03-08 | — | — | US | claimed |
| EP-2040703-B1 | DERIVATIVES OF 2-BENZOYL-IMIDAZOPYRIDINES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2009-10-21 | — | — | EP | claimed |
| US-20090143420-A1 | 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-06-04 | — | — | US | claimed |
| US-7902219-B2 | 2-benzoylimidazopyridine derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-03-08 | — | — | US | disclosed |
| US-20090143420-A1 | 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143420-A1 | 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | NR4A2, NR4A3, NCOR1 | EGLN1 3820/4885PTGS1 2497/4885PTGS2 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.